Drug Search Results
More Filters [+]

Pranlukast

Alternative Names: pranlukast
Latest Update: 2024-05-13
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CYSLT1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Colombia | Dominican Republic | Japan | Korea | Peru | Turkey | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pranlukast

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Sinusitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ONO-1078-37

P3

Completed

Sinusitis

2008-06-01

Recent News Events